Sung Sun Kim

Prof. Sung Sun Kim


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
SKSung Sun Kim
Sung Sun Kim
YCYong Mee Cho
Yong Mee Cho
GKGi Hwan Kim
Gi Hwan Kim
KKKeun Hong Kee
Keun Hong Kee
HKHun-Soo Kim
Hun-Soo Kim
CCChan Choi
Chan Choi

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HKHee Kyung Kim
Hee Kyung Kim
SKSung Sun Kim
Sung Sun Kim
COChan Young Oak
Chan Young Oak
SKSoo Jeong Kim
Soo Jeong Kim
JYJee Hee Yoon
Jee Hee Yoon
HKHo-Cheol Kang
Ho-Cheol Kang
Kim HK, et al. J Korean Med Sci. 2014 Jun;29(6):818-824. https://doi.org/10.3346/jkms.2014.29.6.818

30 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EHEu Chang Hwang
Eu Chang Hwang
SKSung Sun Kim
Sung Sun Kim
HBHyun Jin Bang
Hyun Jin Bang
HKHyeon-Jong Kim
Hyeon-Jong Kim
HSHyun Jeong Shim
Hyun Jeong Shim
SCSang-Hee Cho
Sang-Hee Cho
Background/Objectives: The tumor microenvironment (TME) has emerged as a significant prognostic factor. This study aimed to identify prognostic factors by combining clinicopathologic parameters and the TME biomarkers in patients who underwent surgery following neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC). Methods: CD8+ T cells, CXCR3, CXCL10, and α-smooth muscle actin (α-SMA) were analyzed via immunohistochemical staining. We also incorporated AI-powered digital pathology to assess the spatial TME. The associations between these biomarkers, clinicopathologic parameters, and survival outcomes were evaluated. Results: CD8+ T cell expression, CXCR3 expression in tumor-infiltrating lymphocytes (TILs), and immune phenotypes were correlated. LARC patients with a high expression of CD8+ T cells, CXCR3 in TILs, and an inflamed phenotype had a significantly better prognosis than their counterparts did. In the multivariate analysis, the expression of CD8+ T cells and the inflamed/immune-excluded phenotype were significant tumor immune microenvironment (TiME) biomarkers for recurrence-free survival (RFS) but not for overall survival (OS). Notably, patients with the immune-desert phenotype had a poor prognosis regardless of pathologic stage, even if postoperative chemotherapy was administered (p < 0.001). Conclusions: CD8+ T cells and AI-powered immune phenotypes, alongside clinical factors, can guide personalized treatment in LARC patients receiving nCRT. A therapeutic strategy to modify the TiME after nCRT could help reduce recurrence after surgery.

1 January 2015 in Internal Medicine
Verified
Journal Article
Open access
HKHa Yeon Kim
Ha Yeon Kim
SKSung Sun Kim
Sung Sun Kim
EBEun Hui Bae
Eun Hui Bae
SMSeong Kwon Ma
Seong Kwon Ma
SKSoo Wan Kim
Soo Wan Kim
A 31-year-old woman with no significant past medical or family history was admitted with complaints of general weakness. Laboratory tests revealed: serum potassium 3.0 mEq/L, arterial blood pH 7.28, serum bicarbonate 17.8 mEq/L and urinary pH 7.0. Double-labeling confocal fluorescence microscopy using H(+)-ATPase and pendrin antibodies demonstrated a decreased expression of these proteins in the patient's renal collecting duct compared to normal controls. Anti-Sjögren's-syndrome-related antigen A (Anti-Ro/SS-A) and anti-Sjögren's syndrome type B (anti-La/SS-B) antibodies were strongly positive with very high titers, consistent with Sjögren's syndrome. We present a case of distal renal tubular acidosis-associated Sjögren's syndrome with a defect in H(+)-ATPase and pendrin in the renal collecting duct.

1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
JLJeong Ho Lee
Jeong Ho Lee
SKSung Sun Kim
Sung Sun Kim
SSSoon Ja Seok
Soon Ja Seok
EBEun Hui Bae
Eun Hui Bae
Lee JH, et al. J Korean Med Sci. 2018 Jul;33(37):e230. https://doi.org/10.3346/jkms.2018.33.e230

25 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SYSeong Hyeon Yu
Seong Hyeon Yu
SKSung Sun Kim
Sung Sun Kim
SKShinseung Kim
Shinseung Kim
HLHyungki Lee
Hyungki Lee
TKTaek Won Kang
Taek Won Kang
Background: Mutations of fibroblast growth factor receptor 3 (FGFR3) are associated with urothelial carcinoma (UC) oncogenesis and are considered an important therapeutic target. Therefore, we evaluated the FGFR3 mutation rate and its clinical significance in urothelial carcinoma (UC) using next-generation sequencing. Methods: A total of 123 patients with UC who were treated at Chonnam National University Hospital (Gwang-ju, Korea) from January 2018 to December 2020 were enrolled. We performed NGS using the Oncomine panel with tumor specimens and blood samples corresponding to each specimen. We analyzed the FGFR3 mutation results according to the type of UC and the effects on early recurrence and progression. Results: The mean age of the patients was 71.39 ± 9.33 years, and 103 patients (83.7%) were male. Overall, the FGFR3 mutation rate was 30.1% (37 patients). The FGFR3 mutation rate was the highest in the non-muscle-invasive bladder cancer (NMIBC) group (45.1%), followed by the muscle-invasive bladder cancer (22.7%) and upper tract UC (UTUC) (14.3%) groups. Patients with FGFR3 mutations had a significantly lower disease stage (p = 0.019) but a high-risk of NMIBC (p < 0.001). Conclusions: Our results revealed that FGFR3 mutations were more prevalent in patients with NMIBC and lower stage UC and associated with a high-risk of NMIBC. Large multicenter studies are needed to clarify the clinical significance of FGFR3 mutations in UC.